文献速递外周动脉疾病

Legflow药物涂层球囊治疗股腘动脉闭塞的一年临床结局注册研究

One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
PubMed 文献 · J Endovasc Ther · 2019-01-01

前瞻性多中心注册研究纳入139例股腘动脉病变患者,评估Legflow紫杉醇DCB的安全性和12个月疗效。结论提示该新一代DCB在不同临床和解剖情形下安全有效,但需更长随访和RCT验证。

要点

  • 12个月免于临床驱动靶病变血运重建率83.3%,支架内再狭窄亚组达89.2%。
  • 间歇性跛行患者免于CD-TLR率87.0%,CLI患者78.2%(p=0.20)。

核心结论

  • Legflow紫杉醇DCB治疗股腘动脉闭塞在不同临床和解剖情形下安全有效。
  • 上述数据需更长随访和随机对照试验确认。

研究设计与样本

  • 前瞻性注册研究,2014年1月至2016年6月纳入4家欧洲中心的139例患者(平均年龄67.1±10.8岁,109例男性)。
  • 主要终点为12个月免于二元再狭窄(双功能超声收缩期峰值流速比≥2.4或DSA狭窄>50%),次要终点为12个月免于临床驱动靶病变血运重建(CD-TLR)。

主要发现

  • 住院期间3例CLI患者死于伤口相关并发症,3例CLI患者因早期闭塞(2例)和支架血栓形成(1例)接受紧急TLR。
  • 12个月时另4例患者死于与手术无关的心脏疾病。
  • 132例可随访患者中,107例(81.1%)达到主要终点(免于再狭窄),110例(83.3%)免于CD-TLR。
  • 25例晚期再狭窄>50%中仅3例无症状患者未需TLR;跛行患者免于CD-TLR率87.0%高于CLI患者78.2%(p=0.20);支架内再狭窄患者1年免于TLR率89.2%。

临床怎么用

  • Legflow紫杉醇DCB可作为股腘动脉原发病变、球囊扩张后再狭窄及支架内再狭窄的治療选择。
  • 术后12个月需监测再狭窄和靶病变血运重建,CLI患者事件风险可能高于跛行患者。

局限性

  • 单臂注册研究,无随机对照。
  • 随访时间仅12个月,需更长随访确认。
  • 样本量139例,亚组分析效力有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the 1-year outcomes of the prospective Legflow drug-coated balloon (DCB) registry, which evaluated the safety and 12-month efficacy of the Legflow balloon in the treatment of femoropopliteal disease. METHODS: The Legflow is a new generation of DCB that has a homogenous, stable surface coating incorporating 0.1-µm paclitaxel particles. From January 2014 to June 2016, 139 patients (mean age 67.1±10.8 years; 109 men) were enrolled at 4 European institutions. Seventy-nine (56.8%) patients had claudication, while 60 (43.2%) had critical limb ischemia (CLI). Mean lesion length (MLL) was 90.0±41.2 mm. Eighty (57.6%) patients were treated for de novo lesions (MLL 83.2±41.2 mm), 29 (20.9%) for postangioplasty restenosis (MLL 81.2±30.9 mm), and 30 (21.6%) for in-stent restenosis (MLL 117.0±39.5 mm). The primary outcome measure was freedom from binary restenosis as determined by a peak systolic velocity ratio ≥2.4 on duplex or >50% stenosis on digital subtraction angiography at 12 months. The secondary outcome was freedom from clinically-driven target lesion revascularization (CD-TLR) at 12 months. RESULTS: Technical success was achieved in all the 139 treated patients. During the hospital stay, 3 CLI patients died of wound-related complications and 3 CLI patients underwent urgent TLR due to early occlusion in 2 and stent thrombosis in 1. At 12 months, 4 additional patients died of cardiac disease unrelated to the procedure. Of the 132 patients available for 1-year follow-up, the primary outcome (freedom from restenosis) was obtained in 107 (81.1%) patients. Freedom from CD-TLR was obtained in 110 (83.3%). Of the 25 late restenoses >50%, only 3 asymptomatic patients did not require TLR. Freedom from CD-TLR was higher in claudicants (87.0%) than in CLI patients (78.2%, p=0.20). In patients treated for in-stent restenosis, freedom from TLR at 1 year was 89.2%. CONCLUSION: These data suggest that the use of a new generation paclitaxel-coated balloon represents a safe and effective therapeutic strategy for femoropopliteal obstructions in different clinical and anatomical settings. These data will need to be confirmed with longer-term follow-up and in randomized controlled trials.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Stabile E, Gerardi D, Magliulo F, et al. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry. J Endovasc Ther. 2019. PMID: 30760132. doi:10.1177/1526602818823557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。